IJID regions最新文献

{"title":"Clinical and biological features of acute hepatic cytolysis in dengue fever: a study from Sourô Sanou University hospital, Bobo-Dioulasso","authors":"Zoungrana Jacques ,&nbsp;Sawadogo Abdoulaye ,&nbsp;SIB Tôh ,&nbsp;Zongo-Napon P. Delphine ,&nbsp;Diendere E. Arnaud ,&nbsp;Some Dogbèponé ,&nbsp;Ouedraogo G Arsène ,&nbsp;Diallo Ismael ,&nbsp;Savadogo Mamoudou ,&nbsp;Sondo K. Apoline ,&nbsp;Poda Armel ,&nbsp;Sawadogo Appolinaire","doi":"10.1016/j.ijregi.2025.100812","DOIUrl":"10.1016/j.ijregi.2025.100812","url":null,"abstract":"<div><h3>Objective</h3><div>To describe hepatic cytolysis in patients hospitalized for dengue at the Sourô Sanou University Hospital in Bobo-Dioulasso.</div></div><div><h3>Methods</h3><div>This was a cross-sectional, descriptive, retrospective, and analytical study conducted over 3 months. All patients hospitalized for dengue during this timeframe were included. Data were collected using the KoBoCollect v1.30.1 application and analyzed with Epi Info software.</div></div><div><h3>Results</h3><div>A total of 256 patients were included. The mean age was 38.10 ± 16.28 years. Elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were observed in 72.26% and 46.85% of patients, respectively. A reduced prothrombin time was noted in 4.68% of cases, and unconjugated hyperbilirubinemia in 3.9%. Patients with hypertension had a 2.3-fold higher risk of developing hepatic cytolysis. The median length of hospital stay was five days. The case-fatality rate was 7.03%. Transaminase levels normalized in 95.5% of cases, with a mean recovery time of 13 days.</div></div><div><h3>Conclusions</h3><div>Hepatic cytolysis is a common complication of severe dengue. Its clinical course is generally favorable. Hypertension appears to be a significant risk factor for the development of this liver injury.</div></div>","PeriodicalId":73335,"journal":{"name":"IJID regions","volume":"18 ","pages":"Article 100812"},"PeriodicalIF":1.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145791401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating viral hepatitis into yellow fever surveillance—reflections on Modiyinji et al.","authors":"Chutharat Thanchonnang ,&nbsp;Schawanya K. Rattanapitoon ,&nbsp;Patpicha Arunsan ,&nbsp;Nathkapach K. Rattanapitoon","doi":"10.1016/j.ijregi.2025.100829","DOIUrl":"10.1016/j.ijregi.2025.100829","url":null,"abstract":"","PeriodicalId":73335,"journal":{"name":"IJID regions","volume":"18 ","pages":"Article 100829"},"PeriodicalIF":1.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147538621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the Letter to the Editor regarding “Integrating viral hepatitis into yellow fever surveillance—reflections on Modiyinji et al.”","authors":"Modiyinji Abdou Fatawou,&nbsp;Simo Tchetgna Huguette,&nbsp;Ngu Njei Abanda,&nbsp;Njouom Richard","doi":"10.1016/j.ijregi.2025.100828","DOIUrl":"10.1016/j.ijregi.2025.100828","url":null,"abstract":"","PeriodicalId":73335,"journal":{"name":"IJID regions","volume":"18 ","pages":"Article 100828"},"PeriodicalIF":1.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147538622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review Thank You List, 2025","authors":"","doi":"10.1016/S2772-7076(26)00042-1","DOIUrl":"10.1016/S2772-7076(26)00042-1","url":null,"abstract":"","PeriodicalId":73335,"journal":{"name":"IJID regions","volume":"18 ","pages":"Article 100878"},"PeriodicalIF":1.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147538623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The annual recurrence of dengue in Bangladesh: A persistent threat","authors":"Tushar Ahmed Shishir,&nbsp;Nazifa Tabassum Tasnim,&nbsp;Akash Ahmed","doi":"10.1016/j.ijregi.2025.100835","DOIUrl":"10.1016/j.ijregi.2025.100835","url":null,"abstract":"<div><div>This letter explores the annual recurrence of dengue infections in Bangladesh, a persistent threat to public health and well-being. We examine the cyclical nature of dengue infection across different regions, focusing on densely populated cities such as Dhaka and Chittagong. We also highlighted the challenges during the dengue epidemic by describing potential strategies for combating the spread, highlighting the severe health impacts on public health in high-prevalence areas such as Chittagong, Khulna, and Barisal. Recognizing dengue’s wide-reaching impact on health and daily life, we brainstorm the possible long and short-term solutions to prevent perpetuated future outbreaks.</div></div>","PeriodicalId":73335,"journal":{"name":"IJID regions","volume":"18 ","pages":"Article 100835"},"PeriodicalIF":1.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-exposure prophylaxis in Guyana: linking key populations and other vulnerable groups","authors":"Alisa Khan ,&nbsp;Tariq Jagnarine","doi":"10.1016/j.ijregi.2025.100823","DOIUrl":"10.1016/j.ijregi.2025.100823","url":null,"abstract":"<div><h3>Objectives</h3><div>Despite the introduction of pre-exposure prophylaxis (PrEP) in Guyana as an effective HIV prevention tool, its uptake remains low among key and vulnerable populations, such as men who have sex with men, sex workers, and transgender individuals. This study assessed awareness, uptake, and barriers to PrEP among seronegative individuals in Guyana and proposed strategies to improve accessibility and use.</div></div><div><h3>Methods</h3><div>A cross-sectional, mixed-method study was conducted among 90 seronegative adults across Regions 3, 4, 6, and 10. Quantitative data were collected via structured questionnaires, whereas qualitative insights were gathered through interviews and focus group discussions. Statistical analyses (chi-square) and thematic coding were applied.</div></div><div><h3>Results</h3><div>Among participants, 59% were aware of PrEP, primarily through media sources (43%), whereas only 18% had ever been offered PrEP by a health care provider. None of the participants were active users. The key barriers identified were limited access (48%), fear of side effects (27%), and inadequate provider engagement. However, 57% expressed willingness to use PrEP and 74% would recommend it to peers.</div></div><div><h3>Conclusions</h3><div>PrEP awareness in Guyana is moderate but constrained by systemic barriers, misinformation, and health care inaccessibility. Strengthening provider training, integrating PrEP into routine services, and community outreach are essential to improve uptake.</div></div>","PeriodicalId":73335,"journal":{"name":"IJID regions","volume":"18 ","pages":"Article 100823"},"PeriodicalIF":1.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145925891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence for Africa: bridge or barrier for infectious disease control?","authors":"Francesco Branda ,&nbsp;Ntuli A. Kapologwe","doi":"10.1016/j.ijregi.2026.100863","DOIUrl":"10.1016/j.ijregi.2026.100863","url":null,"abstract":"","PeriodicalId":73335,"journal":{"name":"IJID regions","volume":"18 ","pages":"Article 100863"},"PeriodicalIF":1.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147420617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elimination of Hepatitis B virus transmission in an endemic area in Western Alaska","authors":"Brian J McMahon ,&nbsp;Janet M Johnston ,&nbsp;Lesleigh Kowalski ,&nbsp;Mary Snowball ,&nbsp;Michael G Bruce ,&nbsp;Nathan Furukawa ,&nbsp;Karen Miernyk ,&nbsp;Lisa Townshend-Bulson","doi":"10.1016/j.ijregi.2025.100774","DOIUrl":"10.1016/j.ijregi.2025.100774","url":null,"abstract":"<div><h3>Objectives</h3><div>In the US, hepatitis B virus (HBV) is only endemic in western Alaska, where 90% of the population are Alaska Native (AN) peoples; in the 1970s, the incidence of hepatocellular carcinoma (HCC) in children was the highest in the world. In the 1980s, we screened 53,860 AN peoples for HBV infection, administered HBV vaccine to 43,618 HBV seronegative persons, and initiated universal newborn vaccination. In this study, we examine the impact of this effort 40 years later.</div></div><div><h3>Methods</h3><div>This is a population-based outcome study. We used vaccine and electronic health records to examine rates of newborn vaccination between 2015 and 2019 and changes in HBV incidence rates, as well as the prevalence of HCC in persons under 30 years of age over a 50-year period.</div></div><div><h3>Results</h3><div>Between 2015 and 2019, approximately 90% of newborns received an HBV birth dose, and over 80% received a second HBV vaccine dose by 18 months of age. Annual incidence of new hepatitis B surface antigen-positive tests among AN peoples ranged from 1.4-2.6 per 100,000, down from 6.2 between 1993 and 1997. No hepatitis B surface antigen-positive or HCC cases have been identified in AN peoples under 20 since 1993.</div></div><div><h3>Conclusions</h3><div>Mass population-based vaccination of seronegative persons, with continuing universal newborn immunization, halted transmission of HBV in western Alaska.</div></div>","PeriodicalId":73335,"journal":{"name":"IJID regions","volume":"17 ","pages":"Article 100774"},"PeriodicalIF":1.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145321256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: elevating fingernail hygiene in parasitic disease prevention — implications from Hajipour and Valizadeh’s study","authors":"Nathkapach Kaewpitoon Rattanapitoon ,&nbsp;Chutharat Thanchonnang ,&nbsp;Schawanya Kaewpitoon Rattanapitoon","doi":"10.1016/j.ijregi.2025.100762","DOIUrl":"10.1016/j.ijregi.2025.100762","url":null,"abstract":"<div><div>The recent study by Hajipour and Valizadeh reveals a high prevalence of intestinal parasitic infections in fingernail debris across occupational and demographic groups in Iran. In this letter, we contextualize their findings with global evidence, highlighting the significance of fingernails as hidden reservoirs of parasitic transmission. We propose the integration of fingernail hygiene—specifically, nail trimming and handwashing—into public health interventions, particularly, in endemic and underserved communities. Emphasizing the One Health approach, we underscore the potential of this low-cost strategy in controlling human and zoonotic parasitic infections.</div></div>","PeriodicalId":73335,"journal":{"name":"IJID regions","volume":"17 ","pages":"Article 100762"},"PeriodicalIF":1.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145267912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A prospective double-blind randomized phase III clinical study","authors":"Subhash Thuluva ,&nbsp;Vikram Paradkar ,&nbsp;SubbaReddy Gunneri ,&nbsp;Vijay Yerroju ,&nbsp;Rammohan Reddy Mogulla ,&nbsp;Kamal Thammireddy ,&nbsp;Siddalingaiah Ningaiah ,&nbsp;Chirag Dhar ,&nbsp;Akshay Binayke ,&nbsp;Aymaan Zaheer ,&nbsp;Amit Awasthi ,&nbsp;Shiva Narang ,&nbsp;Naveen Chander Reddy ,&nbsp;Anil Kumar Pandey ,&nbsp;Chitta Sitaram Anjaneylu","doi":"10.1016/j.ijregi.2025.100786","DOIUrl":"10.1016/j.ijregi.2025.100786","url":null,"abstract":"<div><h3>Objectives</h3><div>Vaccines against COVID-19 significantly reduced symptomatic disease and hospitalization. However, waning and diminished protection against emerging variants of concern (VoCs) have warranted booster doses. Clinical studies comparing homologous and heterologous boosters demonstrate enhanced immunogenicity and breakthrough-infection control with heterologous regimens. In this context, we evaluated the safety and immunogenicity of a single heterologous CORBEVAX™ booster in adults in a prospective phase III, randomized, double-blind, placebo-controlled trial.</div></div><div><h3>Methods</h3><div>Adults (18-80 years) previously primed ≥6 months earlier with two doses of COVISHIELD™ or COVAXIN™ were randomized 3:1 within each prime group to receive CORBEVAX™ or placebo. Study endpoints included safety, reactogenicity, tolerability, and humoral/cellular immunogenicity.</div></div><div><h3>Results</h3><div>A total of 416 participants (208 per prime group) were enrolled. Post-CORBEVAX™ booster, we observed enhanced humoral responses—significantly increased neutralizing-antibody titers and anti-receptor-binding domain immunoglobulin G—and a T helper 1-skewed cellular response with increased interferon-gamma secretion. A superior post-booster neutralization response against the Omicron VoC was also observed. Adverse events were primarily mild-to-moderate (no adverse events of special interest) with a booster safety profile comparable to placebo. One serious adverse event occurred and was deemed unrelated to the booster.</div></div><div><h3>Conclusions</h3><div>In conclusion, heterologous boosting with CORBEVAX™ substantially enhanced humoral and cellular immunity against SARS-CoV-2 VoCs while being well tolerated.</div></div>","PeriodicalId":73335,"journal":{"name":"IJID regions","volume":"17 ","pages":"Article 100786"},"PeriodicalIF":1.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145416916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}